The market was valued at USD 14.53 billion in 2024 and is projected to reach USD 106.00 billion by 2035. This represents a remarkable compound annual growth rate (CAGR) of 19.8% during the forecast period from 2025 to 2035.
Global Biomarker Discovery Outsourcing Services Market Size, Opportunity Analysis and Forecast, 2025-2035
Global Biomarker Discovery Outsourcing Services Market Size, Trend & Opportunity Analysis Report, by Type (Predictive, Safety), Therapeutic Area (Oncology, Neurology), and Forecast, 2025-2035
Report Code: LSDB209Author Name: Dhwani SharmaPublication Date: August 2025Pages: 292
Available In:
Global Biomarker Discovery Outsourcing Services Market Size, Opportunity Analysis and Forecast, 2025-2035
Publication Date: Aug 26, 2025Pages: 292
Biomarker Discovery Outsourcing Services Market Definition and Introduction
The Global Biomarker Discovery Outsourcing Services Market, valued at USD 17.41 Billion in 20245 is projected to soar to USD 108.25 Billion by 2035, expanding at a remarkable CAGR of 20.05% during the forecast period 2025-2035. Biomarkers have become critical in early diagnosis, therapy targeting, and treatment efficacy monitoring in precision medicine. By outsourcing the biomarker discovery activity, pharmaceutical companies, biotech innovators, and research institutes can speed the timelines for research and development (R&D), lighten infrastructure burdens, and gain access to cutting-edge analytical platforms at a fraction of the expense. Today's drug development involves sophisticated biology, high bioinformatics engine capacity, and laboratory capabilities in which contract research organizations (CROs) and specialized biomarker service providers have expertise.
Key Market Trends & Analysis
- Biomarker Discovery Outsourcing Services Market size reached USD 17.41 Billion, reflecting strong demand from precision medicine and drug development.
- The market is projected to expand at a CAGR of 20.05% from 2025 through 2035, driven by outsourcing.
- Market size is forecast to reach USD 108.25 Billion by 2035, supported by increasing biomarker integration across clinical trials.
- Growing drug development complexity is accelerating outsourcing demand for specialized infrastructure, analytical expertise, and advanced biomarker discovery platforms.
- Predictive biomarkers dominate market share as pharmaceutical companies increasingly use biomarkers for patient stratification and personalized treatment strategies.
- Safety biomarkers are gaining traction by supporting toxicity assessment, risk mitigation, and improved drug safety monitoring throughout development.
- Oncology dominates therapeutic applications, driven by molecular profiling, targeted therapies, immuno-oncology, and increasing companion diagnostic requirements.
- North America leads the market, supported by a strong biopharmaceutical ecosystem, advanced R&D infrastructure, CRO networks, and regulatory expertise.
- Asia-Pacific is the fastest-growing region, fueled by expanding biopharmaceutical activity, clinical trials, and cost-efficient biomarker outsourcing capabilities.
- Thermo Fisher Scientific, Charles River Laboratories, and Quest Diagnostics are advancing biomarker capabilities through expanded services, collaborations, and standardized testing infrastructure.
Biomarker Discovery Outsourcing Services Market Size and Growth Projection:
- Market Size: USD 17.4 Billion (2025)
- Market Size in Forecast Year: USD 108.25 Billion (2035)
- CAGR: 20.05%
- Base Year: 2025
- Forecast Period: 2025-2035
- Historical Data: 2022, 2023, 2024
Consistent with regulatory authorities' emphasis on companion diagnostics and real-world evidence, biomarkers have evolved from an added-on activity to a pivotal strategic necessity in the drug development pipeline. Outsourcing also has the potential to fill capability voids, but most importantly, it brings speed of response to sponsors when it becomes necessary to shift research direction because of interim findings or newly emerging therapeutic trends. The same is true for oncology, where the driving force for personalized therapy is molecular heterogeneity: external partners are increasingly relied upon to perform multi-omics profiling, high-throughput screening, and validation studies in large and diverse patient cohorts. Neurology is also going in that direction: the unmet need is for diagnostic precision in disorders like Alzheimer's and Parkinson's, which has opened the door to demand for new biomarkers that detect pathologies even earlier and then follow disease progression more reliably.
AI and machine learning (ML) are emerging in biomarker analytics to cause a paradigm shift in the delivery model of services, which would allow the outsourced partners to integrate large-scale datasets of genomics, proteomics, and metabolomics for predictive modeling. Furthermore, the increasingly urgent demand for the global biopharma ecosystem to improve clinical trial success rates creates an even greater impetus for outsourcing biomarker discovery as a lever to better patient stratification, cost reduction, and faster market access. These factors would create the perfect environment between sponsors and service providers, wherein innovation, compliance with regulations, and speed to market would add up to a competitive advantage.
Recent Developments in the Biomarker Discovery Outsourcing Services Industry
- In March 2024, Thermo Fisher Scientific unveiled an expanded biomarker discovery service suite integrating genomics, proteomics, and metabolomics, enabling pharmaceutical companies to accelerate target identification and validation. The service leverages AI-driven analytics to enhance the precision of predictive biomarkers in oncology and neurology.
- In June 2024, Charles River Laboratories entered into a collaboration with a leading biotech company to advance biomarker identification in neurodegenerative disorders. The partnership aims to streamline biomarker validation pipelines and facilitate earlier patient stratification in Alzheimer-s clinical trials.
- In January 2024, Quest Diagnostics established a global biomarker testing hub designed to support multinational clinical trials with standardized methodologies. This initiative enhances turnaround times, data consistency, and compliance with international regulatory frameworks.
Biomarker Discovery Outsourcing Services Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
The complexity in the drug development process is a capital thrust for future outsourced biomarker discovery services.
More and more, precision medicine has initiated hurdles in integration with biomarker-driven endpoints for drug developers. As a result, companies are now looking at outsourcing for the immediate availability of specialized infrastructure and domain-specific talent, as well as analytical platforms, though to minimize risk and speed up discovery timelines.
Cancer and neurology are becoming the driving forces in advancing various biomarker outsourcing engagements.
With immunotherapy now receiving more attention on cancer in addition to targeted therapies, and diagnostics becoming an essential part of treatment for neurodegenerative diseases, this has created severe specific demand for biomarker customer pipelines. CROs and niche service organizations rush in and fill those by delivering high-dimensional data analysis, bioinformatics integration, and validation across very different demographics.
The heightened interest in regulations in companion diagnostics has made biomarker discovery a concern at strategic levels.
Increasingly, regulatory authorities like the FDA and EMA are requiring drugs to have companion diagnostics when submitting them for approval, particularly for oncology drugs. In turn, this environment is increasingly pushing pharmaceutical companies to outsource biomarker discovery, ensure that drugs meet the regulatory requirements, match clinical endpoints, and therefore have these clearances faster.
The ARTAGE of AI-Driven Bioinformatics Technology Revolutionizes the Biomarker Discovery Workflow.
Innovative algorithms embedded in machine learning paired with data integration platforms can discover complex, multi-analyte biomarker signatures. Outsourcing, taking advantage of sophisticated predictive modeling tools, will offer models that have better predictive accuracy, eventually attaining better patient stratification in clinical trials.
Where Are the Biggest Opportunities in the Biomarker Discovery Outsourcing Services Market?
- AI-Powered Biomarker Discovery - Leveraging machine learning to enhance predictive accuracy in oncology and neurology
- Companion Diagnostics Growth - Rising co-development of drugs and diagnostics driving outsourced biomarker partnerships
- Multi-Omics Integration - Comprehensive genomic, proteomic, and metabolomic profiling services gaining market traction
- Neurology Breakthroughs - Discovery of early-stage biomarkers for Alzheimer-s and Parkinson-s diagnostics
- Emerging Markets Demand - Expansion of biomarker services in APAC-s growing pharmaceutical and biotech hubs
- Regulatory Alignment - Services tailored to meet stringent FDA, EMA, and PMDA biomarker validation requirements
- Strategic Alliances - Collaborations between CROs, biopharma, and diagnostic companies for end-to-end biomarker solutions
- Clinical Trial Optimization - Biomarkers reducing trial attrition through improved patient selection and monitoring
Biomarker Discovery Outsourcing Services Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 17.4 Billion |
Market Size by 2035 | USD 108.25 Billion |
CAGR (2026-2035) | 20.05% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Type: Predictive, Safety By Therapeutic Area: Oncology, Neurology |
Regional Analysis/Coverage | North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa) |
Company Profiles | Thermo Fisher Scientific, Charles River Laboratories, Eurofins Scientific, Bio-Rad Laboratories, Quest Diagnostics, Laboratory Corporation of America (LabCorp), ICON plc, Evotec AG, PPD (part of Thermo Fisher), and Medpace. |
Biomarker Discovery Outsourcing Market: Dominating Segments
In the biomarker discovery outsourcing market, the predictive biomarkers segment has been found to be the driver, due to the acceptance of personalized medicine.
Predictive biomarkers, in essence, predict therapeutic outcomes and inform decisions regarding targeting therapy. The high demand for predictive biomarker discovery and validation services, which are mostly outsourced, comes from the therapy area of rapidly developing
oncology trials and precision drug development for neurology.
Oncology is a prominent therapeutic area in advanced clinical trials molecular profiling requirements.
For biomarker outsourcing, oncology remains the top therapeutic area due to the complexities involved in cancer biology that necessitate extensive molecular profiling and companion diagnostic development. A growing need for specialized biomarker capabilities has been generated due to the typical acceptance of immuno-oncology drugs and targeted therapies.
The safety biomarkers segment steadily moves forward in drug development risk mitigation strategies.
Safety biomarkers, which monitor toxicity and side effects, have gained traction in various therapeutic pipelines. These outsourced partners have the advances in assays and validation systems necessary to ensure these biomarkers are effectively integrated into preclinical and clinical programs.
Regional Insights in the Biomarker Discovery Outsourcing Market
North America is at the forefront of the industry because of a very strong biopharma presence backed by state-of-the-art R&D infrastructure.
North America, by the United States, is the leading continent in the biomarker outsourcing market because of its robust and mature pharmaceutical system, a solid, well-established network of CROs, and good investment capacity into precision medicine research. The increased regulatory impetus on companion diagnostics further drives demand for the services in the region.
Europe will speed up adopting biomarker-based diagnostics, driven by regulatory strictness and innovation centers.
European countries, including the UK, Germany, and France, create an environment in which biomarker innovation is enhanced by clustering research, government-public partnership, and strict adherence to EMA requirements. These features make Europe a leader in the uptake of high-rated biomarker outsourcing services.
Asia-Pacific is the fastest expanding region owing to ever-increasing biopharma growth and clinical trial activities.
China, India, and South Korea are witnessing a phenomenal increase in biomarker outsourcing demand, mainly driven by their booming pharmaceutical manufacturing, increasing participation in clinical trials, and government incentives to spur biotech innovation. Also increasing the growth prospect is a cost-efficient yet technologically advanced CRO landscape in the APAC region.
How Can Stakeholders Benefit from the Biomarker Discovery Outsourcing Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Questions
Oncology is the leading therapeutic area. This dominance is driven by the molecular heterogeneity of cancer, the rise of immuno-oncology, and the increasing regulatory requirement for companion diagnostics to support targeted therapies.
Outsourcing allows sponsors to accelerate R&D timelines, reduce heavy infrastructure costs, and access specialized expertise in bioinformatics and high-throughput screening. It also provides the flexibility to shift research directions quickly based on interim clinical findings.
AI and ML are causing a paradigm shift by enabling the integration of massive datasets across genomics, proteomics, and metabolomics. These technologies allow outsourced partners to develop predictive models with higher accuracy, improving patient stratification in clinical trials.
Predictive biomarkers are the primary market driver as they help predict therapeutic outcomes and inform decisions on targeted therapies. Safety biomarkers are used for risk mitigation, helping developers monitor toxicity and side effects during preclinical and clinical programs.
North America, led by the United States, is the dominant region. Its leadership is attributed to a mature pharmaceutical ecosystem, a well-established network of Contract Research Organizations (CROs), high investment in precision medicine, and a strong regulatory focus on companion diagnostics.
The Asia-Pacific (APAC) region is the fastest-growing market. Growth is fueled by booming pharmaceutical manufacturing in China and India, increasing participation in global clinical trials, and government incentives designed to spur biotech innovation.
Regulatory bodies are increasingly requiring drugs—particularly in oncology—to be submitted alongside companion diagnostics. This strategic necessity pushes pharmaceutical companies to seek outsourced expertise to ensure compliance and achieve faster market clearance.
In 2024, Thermo Fisher Scientific expanded its multi-omics service suite; Charles River Laboratories collaborated with a major biotech firm to advance neurodegenerative biomarkers; and Quest Diagnostics established a global biomarker testing hub to standardize methodologies for multinational trials.
Significant opportunities include the development of AI-powered discovery platforms, the discovery of early-stage biomarkers for neurology (Alzheimer’s and Parkinson’s), the integration of multi-omics profiling, and the expansion of services into emerging APAC biopharma hubs.
